Hearing Loss in Patients With Vestibulotoxic Reactions to Gentamicin Therapy
Open Access
- 1 March 2006
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 132 (3), 253-257
- https://doi.org/10.1001/archotol.132.3.253
Abstract
Aminoglycosides can cause permanent damage to inner ear hair cells, resulting in hearing loss (cochleotoxicity) and/or vestibular disturbances such as disequilibrium (vestibulotoxicity). Gentamicin, an aminoglycoside that is widely used parenterally to treat serious infections, is considered to be more vestibulotoxic than cochleotoxic.1 Black et al2 reported a clinical series of 33 adult patients, seen at a tertiary neurotology clinic a year or more after gentamicin therapy, all of whom had disabling vestibular symptoms beginning after gentamicin therapy as well as vestibulotoxic reactions documented by objective tests of vestibulo-ocular reflex function. Twenty-seven of the 33 patients underwent audiometry, including pure-tone and speech thresholds and speech intelligibility tests; 17 of these 27 had sensorineural hearing loss thought to be attributable to cochleotoxic effects of gentamicin. However, this group was predominantly middle aged (mean age, 55 years) and male (63%); age and male sex are strong predictors of sensorineural hearing loss. In the absence of pretreatment audiometry in any of these cases, it is difficult, as Black et al2 acknowledged, to estimate the magnitude of the cochleotoxic insult.Keywords
This publication has 13 references indexed in Scilit:
- Chapter 17: Prediction and Analysis of the Hearing Characteristics of Noise-Exposed Populations or IndividualsPublished by American Industrial Hygiene Association (AIHA) ,2009
- Audiologic Testing and Molecular Analysis of 12S rRNA in Patients Receiving AminoglycosidesThe Laryngoscope, 2005
- Permanent Gentamicin VestibulotoxicityOtology & Neurotology, 2004
- Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside TherapyAntimicrobial Agents and Chemotherapy, 2001
- Statistics with Confidence.Heart, 2001
- High-Frequency Audiometric Monitoring Strategies for Early Detection of OtotoxicityEar & Hearing, 1994
- Risk Factors for the Development of Auditory Toxicity in Patients Receiving AminoglycosidesThe Journal of Infectious Diseases, 1984
- Double-Blind Comparison of the Nephrotoxicity and Auditory Toxicity of Gentamicin and TobramycinThe New England Journal of Medicine, 1980
- Ototoxic Effects of GentamicinJAMA Otolaryngology–Head & Neck Surgery, 1970
- Hearing Levels of Adults by Age and Sex, United States, 1960-1962Journal of Occupational and Environmental Medicine, 1966